APA (7th ed.) Citation

Tuttle, K. R., Hauske, S. J., Canziani, M. E., Caramori, M. L., Cherney, D., Cronin, L., . . . Rossing, P. (2024). Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: A randomised, controlled, phase 2 trial. The lancet, 403(10424), . https://doi.org/10.1016/S0140-6736(23)02408-X

Chicago Style (17th ed.) Citation

Tuttle, Katherine R., et al. "Efficacy and Safety of Aldosterone Synthase Inhibition with and Without Empagliflozin for Chronic Kidney Disease: A Randomised, Controlled, Phase 2 Trial." The Lancet 403, no. 10424 (2024). https://doi.org/10.1016/S0140-6736(23)02408-X.

MLA (9th ed.) Citation

Tuttle, Katherine R., et al. "Efficacy and Safety of Aldosterone Synthase Inhibition with and Without Empagliflozin for Chronic Kidney Disease: A Randomised, Controlled, Phase 2 Trial." The Lancet, vol. 403, no. 10424, 2024, https://doi.org/10.1016/S0140-6736(23)02408-X.